# US 2010/0074878 A1 · Probiotic bacterium: lactobacillus fermentum

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074878 A1
- Document ID: US20100074878A1
- Status: Published application
- Kind: A1
- Application number: 12/384,336
- Filed: 2009-04-02
- Published: 2010-03-25
- Earliest claimed: 2002-09-06
- Assignees: VRI Biomedical LTD
- Inventors: Patricia Lynne Conway
- Web page: https://patentgrep.com/patent/US20100074878A1

## CPC

- C12N 1/205: Bacterial isolates
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 1/10: Laxatives
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 17/00: Drugs for dermatological disorders
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/04: Amoebicides
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/143: Fermentum
- C12R 2001/225: Lactobacillus
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Variant of the bacterium Lactobacillus fermentum and its use in treating gastrointestinal disorders, disorders of the mucosal surfaces or disturbances in the immune system or status of a subject.

## Claims

### Claim 1

A Lactobacillus fermentum variant having the following characteristics:
(a) it is a Gram positive, facultative rod,
(b) it ferments ribose, galactose, glucose, fructose, mannose, maltose, lactose, melibiose, sucrose, trehalose, raffinose, L-arabinose and mannitol,
(c) it survives at pH 1.5 for up to 4 hours with a loss in growth of no more than log 3,
(d) it propagates in the presence of 0.5% bile salts at 37 C resulting in an increase in optical density of 0.5 to 0.8,
(e) it is stable when stored in, gelatin capsules at 25 C,
(f) it adheres to Peyer's Patches at greater than log 5 cfu per mg tissue inhibiting pathogens both by a direct antagonistic effect and by triggering an immune modulation;
or a component thereof.

### Claim 2 (depends on 1)

A Lactobacillus fermentum variant according to claim 1, wherein said variant is VRI 003 (accession no. NM02/31074).

### Claim 3 (depends on 1)

A component of a Lactobacillus fermentum variant according to claim 1, wherein said component is a cell fragment, extract, secretion or purified component.

### Claim 4 (depends on 1)

A composition comprising a Lactobacillus fermentum variant according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

A composition according to claim 4, further comprising a prebiotic, a nondigestible dietary component, dietary fibre or a pharmaceutically active compound.

### Claim 6 (depends on 5)

A composition according to claim 5, wherein the prebiotic is inulin, a resistant starch, an oligosaccharide, a gum or a beta-glucan.

### Claim 7 (depends on 6)

A composition according to claim 6, wherein said prebiotic is unmodified high amylose starch or beta-glucan.

### Claim 8 (depends on 4)

A composition according to claim 4, wherein said composition comprises live cells of the Lactobacillus fermentum variant.

### Claim 9 (depends on 4)

A composition according to claim 4, wherein said composition comprises dead cells of the Lactobacillus fermentum variant.

### Claim 10 (depends on 4)

A composition according to claim 4, in the form of a tablet, capsule, powder, paste, gel, liquid formulation, dietary supplement or food product.

### Claim 11 (depends on 10)

A composition according to claim 10, wherein said composition is in the form of a tablet.

### Claim 12 (depends on 10)

A composition according to claim 10, wherein said composition is in the form of a food product.

### Claim 13 (depends on 12)

A composition according to claim 12, wherein said food product is a dairy or dairy-based food product.

### Claim 14 (depends on 10)

A composition according to claim 10, wherein said composition is in the form of a liquid formulation.

### Claim 15 (depends on 10)

A composition according to claim 10, wherein said composition is in the form of a dietary supplement.

### Claim 16 (depends on 1)

A method for preventing and/or treating a gastrointestinal disorder or symptoms thereof, comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said composition is administered orally.

### Claim 18 (depends on 16)

A method according to claim 16, wherein said gastrointestinal disorder is irritable bowel syndrome, inflammatory bowel disease, diarrhoea, bloating, flatulence, abdominal cramping, abdominal pain, constipation or Crohn's disease.

### Claim 19 (depends on 16)

A method according to claim 16, wherein said gastrointestinal disorder is caused by a pathogen.

### Claim 20 (depends on 19)

A method according to claim 19, wherein said gastrointestinal disorder is caused by a bacterium, virus or protozoa.

### Claim 21 (depends on 20)

A method according to claim 20, wherein said bacterium is Salmonella, Escherichia coli, Helicobacter, Vibrio or Pseudomonas.

### Claim 22 (depends on 20)

A method according to claim 20, wherein said virus is a Norwalks or rotavirus.

### Claim 23 (depends on 20)

A method according to claim 20, wherein said protozoa is Cryptosporidium, Entamoeba, Giardia or Dientamoeba.

### Claim 24 (depends on 1)

A method for preventing and/or treating a disorder of a mucosal surface and/or symptoms thereof, comprising the step of administering an effective amount of a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 25 (depends on 24)

A method according to claim 24, wherein said disorder is eczema, atopic dermatitis or rosacea.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A method of stimulating IL-12 production in a subject, comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 28 (depends on 1)

A method of up-regulating IFN-γ comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 29 (depends on 1)

A method of inducing a Th 1-type response in a subject, comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 30 (depends on 1)

A method of inhibiting the growth of a pathogen, comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 31 (depends on 1)

A method of modulating indigenous microbes of the gastrointestinal tract, comprising the step of administering a Lactobacillus fermentum variant according to claim 1, to a subject in need of such treatment.

### Claim 32

(canceled)

### Claim 33 (depends on 3)

A composition comprising a component of a Lactobacillus fermentum variant according to claim 3 and a pharmaceutically acceptable carrier.
